Exosome-based tumor antigens–adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA

Biomaterials

Volumn 111, Issue , 2016, Pages 55-65

  Morishita, Masaki ^a   Takahashi, Yuki ^a   Matsumoto, Akihiro ^a   Nishikawa, Makiya ^a   Takakura, Yoshinobu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Cancer vaccine; CpG DNA; Drug delivery; Exosomes; Genetic engineering; Tumor antigens

Indexed keywords

CELLS; COENZYMES; CYTOLOGY; DISEASES; DNA; DRUG DELIVERY; GENETIC ENGINEERING; PROTEINS; TUMORS; VACCINES;

ANTIGEN PRESENTING CELLS; ANTITUMOR EFFECT; CANCER IMMUNOTHERAPY; CANCER VACCINE; EXOSOMES; MICROSCOPIC OBSERVATIONS; PLASMID VECTORS; TUMOR ANTIGEN;

ANTIGENS;

BIOTIN; CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 12P40; INTERLEUKIN 6; LACTADHERIN; PLASMID VECTOR; STREPTAVIDIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; DNA; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B16BL6 CELL LINE; BIOTINYLATION; CELL LINE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; EXOSOME; FLUORESCENCE MICROSCOPY; GENETIC ENGINEERING; LUNG METASTASIS; LUNG TUMOR; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SPLEEN CELL; TUMOR CELL; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CPG ISLAND; DRUG COMBINATION; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; NUDE MOUSE; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CPG ISLANDS; DNA; DRUG COMBINATIONS; EXOSOMES; GENETIC ENGINEERING; IMMUNIZATION; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; TREATMENT OUTCOME;

EID: 84990238381     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.09.031     Document Type: Article

References (54)

1. [1] Romero, P., Cerottini, J., Speiser, D.E., Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol. Immunother. 53 (2004), 249–255.
2. [2] Stevanovic, S., Identification of tumour-associated T-cell epitopes for vaccine development. Nat. Rev. Cancer, 2, 2002 514–514.
3. [3] Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian carcinoma. Nature 474 (2011), 609–615.
4. [4] Batista-Duharte, A., Lindblad, E.B., Oviedo-Orta, E., Progress in understanding adjuvant immunotoxicity mechanisms. Toxicol. Lett. 203 (2011), 97–105.
5. [5] Tritto, E., Mosca, F., De Gregorio, E., Mechanism of action of licensed vaccine adjuvants. Vaccine 27 (2009), 3331–3334.
6. [6] Hamdy, S., Molavi, O., Ma, Z., Haddadi, A., Alshamsan, A., Gobti, Z., et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8 T cell-mediated anti-tumor immunity. Vaccine 26 (2008), 5046–5057.
7. [7] Hubbell, J.A., Thomas, S.N., Swartz, M.A., Materials engineering for immunomodulation. Nature 462 (2009), 449–460.
8. [8] Théry, C., Ostrowski, M., Segura, E., Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9 (2009), 581–593.
9. [9] Llorente, A., Skotland, T., Sylvänne, T., Kauhanen, D., Róg, T., Orłowski, A., et al. Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochimica Biophysica Acta (BBA)-Mo. Cell Biol. Lipids 1831 (2013), 1302–1309.
10. [10] Morelli, A.E., Larregina, A.T., Shufesky, W.J., Sullivan, M.L., Stolz, D.B., Papworth, G.D., et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 104 (2004), 3257–3266.
11. [11] Sun, Y., Liu, J., Potential of Cancer cell–derived exosomes in clinical application: a review of recent Research advances. Clin. Ther. 36 (2014), 863–872.
12. [12] Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., Wood, M.J., Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29 (2011), 341–345.
13. [13] Cooper, J.M., Wiklander, P., Nordin, J.Z., Al-Shawi, R., Wood, M.J., Vithlani, M., et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov. Disord. 29 (2014), 1476–1485.
14. [14] Zhuang, X., Xiang, X., Grizzle, W., Sun, D., Zhang, S., Axtell, R.C., et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol. Ther. 19 (2011), 1769–1779.
15. [15] Liu, Y., Li, D., Liu, Z., Zhou, Y., Chu, D., Li, X., et al. Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse. Sci. Rep., 5, 2015, 17543.
16. [16] Wilson, K.D., de Jong, S.D., Tam, Y.K., Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. Adv. Drug Deliv. Rev. 61 (2009), 233–242.
17. [17] Diwan, M., Tafaghodi, M., Samuel, J., Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J. Control. Release 85 (2002), 247–262.
18. [18] San Román, B., Irache, J.M., Gómez, S., Tsapis, N., Gamazo, C., Espuelas, M.S., Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. Eur. J. Pharm. Biopharm. 70 (2008), 98–108.
19. [19] Morishita, M., Takahashi, Y., Nishikawa, M., Sano, K., Kato, K., Yamashita, T., et al. Quantitative analysis of tissue distribution of the B16BL6-Derived exosomes using a streptavidin–lactadherin fusion protein and iodine-125-labeled biotin derivative after intravenous injection in mice. J. Pharm. Sci. 104 (2015), 705–713.
20. [20] Cafri, G., Sharbi-Yunger, A., Tzehoval, E., Eisenbach, L., Production of LacZ inducible T cell hybridoma specific for human and mouse gp100 25–33 peptides. PloS one, 8, 2013, e55583.
21. [21] Takahashi, Y., Nishikawa, M., Shinotsuka, H., Matsui, Y., Ohara, S., Imai, T., et al. Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. J. Biotechnol. 165 (2013), 77–84.
22. [22] Théry, C., Amigorena, S., Raposo, G., Clayton, A., Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. cell Biol., 30, 2006 3.22, 1–3.
23. [23] Gastpar, R., Gehrmann, M., Bausero, M.A., Asea, A., Gross, C., Schroeder, J.A., et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res. 65 (2005), 5238–5247.
24. [24] Théry, C., Zitvogel, L., Amigorena, S., Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2 (2002), 569–579.
25. [25] Jäger, E., Jäger, D., Knuth, A., Antigen-specific immunotherapy and cancer vaccines. Int. J. Cancer 106 (2003), 817–820.
26. [26] Dai, S., Wei, D., Wu, Z., Zhou, X., Wei, X., Huang, H., et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol. Ther. 16 (2008), 782–790.
27. [27] Chaiet, L., Wolf, F.J., The properties of streptavidin, a biotin-binding protein produced by Streptomycetes. Arch. Biochem. Biophys. 106 (1964), 1–5.
28. [28] Le Trong, I., Wang, Z., Hyre, D.E., Lybrand, T.P., Stayton, P.S., Stenkamp, R.E., Streptavidin and its biotin complex at atomic resolution. Acta Crystallogr. Sect. D. Biol. Crystallogr. 67 (2011), 813–821.
29. [29] Deng, L., Broom, A., Kitova, E.N., Richards, M.R., Zheng, R.B., Shoemaker, G.K., et al. Kinetic stability of the streptavidin–biotin interaction enhanced in the gas phase. J. Am. Chem. Soc. 134 (2012), 16586–16596.
30. [30] Imai, T., Takahashi, Y., Nishikawa, M., Kato, K., Morishita, M., Yamashita, T., et al. Macrophage-dependent clearance of systemically administered B16BL6-derived exosomes from the blood circulation in mice. J. Extracell. Vesicles, 4, 2015, 26238.
31. [31] Miconnet, I., Koenig, S., Speiser, D., Krieg, A., Guillaume, P., Cerottini, J.C., et al. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J. Immunol. 168 (2002), 1212–1218.
32. [32] Yan, S., Rolfe, B.E., Zhang, B., Mohammed, Y.H., Gu, W., Xu, Z.P., Polarized immune responses modulated by layered double hydroxides nanoparticle conjugated with CpG. Biomaterials 35 (2014), 9508–9516.
33. [33] de Jong, S., Chikh, G., Sekirov, L., Raney, S., Semple, S., Klimuk, S., et al. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol. Immunother. 56 (2007), 1251–1264.
34. [34] Yang, Y., Xiu, F., Cai, Z., Wang, J., Wang, Q., Fu, Y., et al. Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells. J. Cancer Res. Clin. Oncol. 133 (2007), 389–399.
35. [35] Chen, W., Wang, J., Shao, C., Liu, S., Yu, Y., Wang, Q., et al. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur. J. Immunol. 36 (2006), 1598–1607.
36. [36] Gu, X., Erb, U., Büchler, M.W., Zöller, M., Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice. Int. J. Cancer 136 (2015), E74–E84.
37. [37] Xie, Y., Bai, O., Zhang, H., Yuan, J., Zong, S., Chibbar, R., et al. Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8 CTL-and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70. J. Cell Mol. Med. 14 (2010), 2655–2666.
38. [38] Andre, F., Schartz, N.E., Movassagh, M., Flament, C., Pautier, P., Morice, P., et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360 (2002), 295–305.
39. [39] Calzascia, T., Pellegrini, M., Hall, H., Sabbagh, L., Ono, N., Elford, A.R., et al. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J. Clin. Investig. 117 (2007), 3833–3845.
40. [40] Lonsdorf, A.S., Kuekrek, H., Stern, B.V., Boehm, B.O., Lehmann, P.V., Tary-Lehmann, M., Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J. Immunol. 171 (2003), 3941–3946.
41. [41] Zoglmeier, C., Bauer, H., Norenberg, D., Wedekind, G., Bittner, P., Sandholzer, N., et al. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin. Cancer Res. 17 (2011), 1765–1775.
42. [42] Hao, S., Moyana, T., Xiang, J., Review: cancer immunotherapy by exosome-based vaccines. Cancer Biother Radiopharm. 22 (2007), 692–703.
43. [43] Tacken, P.J., Torensma, R., Figdor, C.G., Targeting antigens to dendritic cells in vivo. Immunobiology 211 (2006), 599–608.
44. [44] Haicheur, N., Bismuth, E., Bosset, S., Adotevi, O., Warnier, G., Lacabanne, V., et al. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J. Immunol. 165 (2000), 3301–3308.
45. [45] Bonifaz, L.C., Bonnyay, D.P., Charalambous, A., Darguste, D.I., Fujii, S., Soares, H., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199 (2004), 815–824.
46. [46] Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Théry, C., Masurier, C., et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 7 (2001), 297–303.
47. [47] Andre, F., Schartz, N., Chaput, N., Flament, C., Raposo, G., Amigorena, S., et al. Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine 20 (2002), A28–A31.
48. [48] Rao, Q., Zuo, B., Lu, Z., Gao, X., You, A., Wu, C., et al. Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro. Hepatology 64 (2016), 456–472.
49. [49] Lener, T., Gimona, M., Aigner, L., Borger, V., Buzas, E., Camussi, G., et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J. Extracell. Vesicles, 4, 2015, 30087.
50. [50] Peinado, H., Alečković, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18 (2012), 883–891.
51. [51] Hood, J.L., San, R.S., Wickline, S.A., Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 71 (2011), 3792–3801.
52. [52] Hoshino, A., Costa-Silva, B., Shen, T., Rodrigues, G., Hashimoto, A., Mark, M.T., et al. Tumour exosome integrins determine organotropic metastasis. Nature 527 (2015), 329–335.
53. [53] Bai, J., Xie, X., Lei, Y., An, G., He, L., Chen, R., Consideration of dual characters of exosomes in the tumour immune response. Cell Biol. Int. 38 (2014), 538–545.
54. [54] Kunigelis, K.E., Graner, M.W., The dichotomy of tumor exosomes (TEX) in Cancer immunity: is it all in the ConTEXt?. Vaccines 3 (2015), 1019–1051.